Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Free Cash Flow (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Free Cash Flow for 3 consecutive years, with -$7.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 2.79% to -$7.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$32.7 million, a 8.36% decrease, with the full-year FY2024 number at -$32.8 million, down 55.38% from a year prior.
  • Free Cash Flow was -$7.3 million for Q3 2025 at Mereo BioPharma, up from -$7.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.7 million in Q3 2023 to a low of -$9.4 million in Q4 2024.
  • A 3-year average of -$7.0 million and a median of -$7.8 million in 2023 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 13.59% in 2024; the steepest drop was 382.78% in 2024.
  • Mereo BioPharma's Free Cash Flow stood at -$6.8 million in 2023, then crashed by 38.75% to -$9.4 million in 2024, then rose by 22.41% to -$7.3 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Free Cash Flow are -$7.3 million (Q3 2025), -$7.7 million (Q2 2025), and -$8.3 million (Q1 2025).